493 related articles for article (PubMed ID: 37569598)
1. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance.
Bou Antoun N; Chioni AM
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569598
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
3. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Najafi M; Ahmadi A; Mortezaee K
Cell Biol Int; 2019 Nov; 43(11):1206-1222. PubMed ID: 31136035
[TBL] [Abstract][Full Text] [Related]
4. Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells.
Silva VR; Santos LS; Dias RB; Quadros CA; Bezerra DP
Cancer Commun (Lond); 2021 Dec; 41(12):1275-1313. PubMed ID: 34791817
[TBL] [Abstract][Full Text] [Related]
5. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.
Tang G; Li S; Zhang C; Chen H; Wang N; Feng Y
Acta Pharm Sin B; 2021 Sep; 11(9):2749-2767. PubMed ID: 34589395
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.
Fang Z; Meng Q; Xu J; Wang W; Zhang B; Liu J; Liang C; Hua J; Zhao Y; Yu X; Shi S
Cancer Commun (Lond); 2023 Jan; 43(1):3-41. PubMed ID: 36424360
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
11. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
12. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to EGFR tyrosine kinase inhibitors.
Huang L; Fu L
Acta Pharm Sin B; 2015 Sep; 5(5):390-401. PubMed ID: 26579470
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.
Nagaraju GP; Mezina A; Shaib WL; Landry J; El-Rayes BF
Eur J Cancer; 2016 Jan; 52():109-19. PubMed ID: 26682870
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
17. mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.
Galoian K; Temple HT; Galoyan A
Tumour Biol; 2012 Jun; 33(3):885-90. PubMed ID: 22246604
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
20. Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β-catenin pathway in NSCLC.
Wang J; Zhou P; Wang X; Yu Y; Zhu G; Zheng L; Xu Z; Li F; You Q; Yang Q; Zhuo W; Sun J; Chen Z
Cell Prolif; 2019 May; 52(3):e12592. PubMed ID: 30848009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]